298 related articles for article (PubMed ID: 24628395)
1. A peer support programme for enhancing adherence to oral antipsychotic medication in consumers with schizophrenia.
Boardman G; McCann T; Kerr D
J Adv Nurs; 2014 Oct; 70(10):2293-302. PubMed ID: 24628395
[TBL] [Abstract][Full Text] [Related]
2. Peers experience of delivering a problem-solving programme to enhance antipsychotic medication adherence for individuals with schizophrenia.
Boardman G; Kerr D; McCann T
J Psychiatr Ment Health Nurs; 2015 Aug; 22(6):423-30. PubMed ID: 25944402
[TBL] [Abstract][Full Text] [Related]
3. Medication adherence and significant others' support of consumers with schizophrenia in Australia.
McCann TV; Lu S
Nurs Health Sci; 2009 Sep; 11(3):228-34. PubMed ID: 19689630
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of a peer-led self-management programme for people with schizophrenia: protocol for a randomized controlled trial.
Chan SW; Li Z; Klainin-Yobas P; Ting S; Chan MF; Eu PW
J Adv Nurs; 2014 Jun; 70(6):1425-35. PubMed ID: 24224787
[TBL] [Abstract][Full Text] [Related]
5. The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder.
Byerly MJ; Nakonezny PA; Rush AJ
Schizophr Res; 2008 Mar; 100(1-3):60-9. PubMed ID: 18255269
[TBL] [Abstract][Full Text] [Related]
6. Treatment adherence and insight in schizophrenia.
Bitter I; Fehér L; Tényi T; Czobor P
Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with antipsychotic medication adherence in community-based patients with schizophrenia in Hong Kong: a cross sectional study.
Bressington D; Mui J; Gray R
Int J Ment Health Nurs; 2013 Feb; 22(1):35-46. PubMed ID: 22738372
[TBL] [Abstract][Full Text] [Related]
8. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.
Gilmer TP; Dolder CR; Lacro JP; Folsom DP; Lindamer L; Garcia P; Jeste DV
Am J Psychiatry; 2004 Apr; 161(4):692-9. PubMed ID: 15056516
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
[TBL] [Abstract][Full Text] [Related]
10. Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study.
Brnabic AJ; Kelin K; Ascher-Svanum H; Montgomery W; Kadziola Z; Karagianis J
Int J Clin Pract; 2011 Sep; 65(9):945-53. PubMed ID: 21849009
[TBL] [Abstract][Full Text] [Related]
11. [Relationships between insight and medication adherence in subjects with psychosis].
Droulout T; Liraud F; Verdoux H
Encephale; 2003; 29(5):430-7. PubMed ID: 14615692
[TBL] [Abstract][Full Text] [Related]
12. Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia.
Hong J; Novick D; Brugnoli R; Bertsch J; Haro JM
Hum Psychopharmacol; 2013 Sep; 28(5):438-46. PubMed ID: 23775950
[TBL] [Abstract][Full Text] [Related]
13. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
14. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.
Offord S; Lin J; Mirski D; Wong B
Adv Ther; 2013 Mar; 30(3):286-97. PubMed ID: 23483449
[TBL] [Abstract][Full Text] [Related]
15. A short message service (SMS)-based strategy for enhancing adherence to antipsychotic medication in schizophrenia.
Montes JM; Medina E; Gomez-Beneyto M; Maurino J
Psychiatry Res; 2012 Dec; 200(2-3):89-95. PubMed ID: 22901437
[TBL] [Abstract][Full Text] [Related]
16. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
17. Psychiatrists' awareness of partial- and non-adherence to antipsychotic medication in schizophrenia: results from the Australian ADHES survey.
Kulkarni J; Reeve-Parker K
Australas Psychiatry; 2015 Jun; 23(3):258-64. PubMed ID: 25783668
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of antipsychotic medication taking in people with schizophrenia.
McCann TV; Deans C; Clark E; Lu S
Int J Ment Health Nurs; 2008 Dec; 17(6):428-38. PubMed ID: 19128290
[TBL] [Abstract][Full Text] [Related]
20. Guideline implementation and patient-tailoring strategies to improve medication adherence for schizophrenia.
Hudson TJ; Owen RR; Thrush CR; Armitage TL; Thapa P
J Clin Psychiatry; 2008 Jan; 69(1):74-80. PubMed ID: 18312040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
